<!doctype html> <html> <head><style>
             table { border-collapse: collapse; }
             th, td {
               word-wrap: break-word;
               max-width: 100%;
               font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
               border-bottom: 1px solid #ddd;
               padding: 5px;
               text-align: left;
             }
            tr:hover {background: #f4f4f4;}
            tr:hover .highlighted {background: repeating-linear-gradient(
                    45deg,
                    #ffff99,
                    #ffff99 10px,
                    #f4f4f4 10px,
                    #f4f4f4 20px
                  );}
           .highlighted { background-color: #ffff99; }
          </style></head><body><h2>Tecemotide</h2><br> <b>Section Title</b>: Overview and results of all trials <br><b>Table Section Text</b>: Tecemotide clinical trials (as of September 2, 2014) sorted by (Estimated) Primary Completion Date: <br> <table>
<tr> <th colspan=10 rowspan=1 > Clinical trials: Lung cancer, Breast cancer, Prostate cancer, Colorectal cancer and Multiple myeloma </th></tr>
<tr> <th colspan=1 rowspan=1 > NCT Number / Title </th><th colspan=1 rowspan=1 > Other IDs </th><th colspan=1 rowspan=1 > Start Date </th><th colspan=1 rowspan=1 > (Estimated) Primary Completion Date </th><th colspan=1 rowspan=1 > Recruitment </th><th colspan=1 rowspan=1 > Conditions </th><th colspan=1 rowspan=1 > Interventions </th><th colspan=1 rowspan=1 > Phases </th><th colspan=1 rowspan=1 > Enrollment (Patients) </th><th colspan=1 rowspan=1 > Sponsor / Collaborators </th></tr>
<tr> <td colspan=1 rowspan=2 > NCT00157209 Phase IIb Randomized Controlled Study of BLP25 Liposome Vaccine for Immunotherapy of Non-Small Cell Lung Cancer </td><td colspan=1 rowspan=1 > B25-LG-304 / EMR 63325-005 </td><td colspan=1 rowspan=1 > August 2000 </td><td colspan=1 rowspan=1 > March 2006 </td><td colspan=1 rowspan=1 > Completed </td><td colspan=1 rowspan=1 > Lung Neoplasms, Carcinoma, Non-Small-Cell Lung </td><td colspan=1 rowspan=1 > Biological: BLP25 Liposome Vaccine plus best supportive care; Other: Best Supportive Care (BSC) </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 171 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <td colspan=9 rowspan=1 > Results: A Phase IIb clinical trial of 171 patients with inoperable stage IIIb non-small-cell lung cancer (NSCLC), in which tecemotide showed a trend towards extending median overall survival from 13.3 months for patients receiving best supportive care (BSC) to 30.6 months for patients receiving tecemotide plus BSC. </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT00157196 Safety Study of BLP25 Liposome Vaccine in Non-Small Cell Lung Cancer Patients With Unresectable Stage III Disease </td><td colspan=1 rowspan=1 > B25-LG-305 / EMR 63325-006 </td><td colspan=1 rowspan=1 > April 2005 </td><td colspan=1 rowspan=1 > September 2009 </td><td colspan=1 rowspan=1 > Completed </td><td colspan=1 rowspan=1 > Carcinoma, Non-Small-Cell Lung, Lung Neoplasms </td><td colspan=1 rowspan=1 > Biological: BLP25 Liposome Vaccine </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 22 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <td colspan=1 rowspan=2 > NCT00925548 STRIDE - STimulating Immune Response In aDvanced brEast Cancer </td><td colspan=1 rowspan=1 > STRIDE, EMR 200038-010, 2008-005544-17 </td><td colspan=1 rowspan=1 > September 2009 </td><td colspan=1 rowspan=1 > August 2010 </td><td colspan=1 rowspan=1 > Terminated </td><td colspan=1 rowspan=1 > Breast Cancer </td><td colspan=1 rowspan=1 > Biological: Tecemotide (L-BLP25) and Hormonal Treatment, Biological: Placebo of tecemotide (L-BLP25) and Hormonal Treatment, Drug: cyclophosphamide, Drug: sodium chloride (NaCl) </td><td colspan=1 rowspan=1 > Phase 3 </td><td colspan=1 rowspan=1 > 16 </td><td colspan=1 rowspan=1 > EMD Serono </td></tr>
<tr> <td colspan=9 rowspan=1 > A thirty-site phase III trial (STRIDE) began in September 2009 on 900 women. The purpose of this study is to determine whether the addition of tecemotide to hormonal treatment is effective in prolonging progression-free survival in postmenopausal women with endocrine-sensitive inoperable locally advanced, recurrent or metastatic breast cancer. </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01094548 Study of Stimuvax in Patients With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy </td><td colspan=1 rowspan=1 > EMR63325-008 </td><td colspan=1 rowspan=1 > February 2008 </td><td colspan=1 rowspan=1 > February 2011 </td><td colspan=1 rowspan=1 > Completed </td><td colspan=1 rowspan=1 > Multiple Myeloma </td><td colspan=1 rowspan=1 > Biological: L-BLP25, cyclophosphamide prior to first vaccination, Biological: L-BLP25 </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 34 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <td colspan=1 rowspan=2 > NCT00409188 Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer </td><td colspan=1 rowspan=1 > START, EMR 63325-001 </td><td colspan=1 rowspan=1 > January 2007 </td><td colspan=1 rowspan=1 > August 2012 </td><td colspan=1 rowspan=1 > Completed </td><td colspan=1 rowspan=1 > Non-small Cell Lung Cancer </td><td colspan=1 rowspan=1 > Biological: Tecemotide (L-BLP25), Biological: Placebo </td><td colspan=1 rowspan=1 > Phase 3 </td><td colspan=1 rowspan=1 > 1513 </td><td colspan=1 rowspan=1 > EMD Serono, Merck KGaA </td></tr>
<tr> <td colspan=9 rowspan=1 > Results: The primary endpoint of overall survival was not met in the START trial. However, the exploratory subgroup analysis in the START trial generated a reasonable hypothesis to warrant additional study. </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01731587 Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer </td><td colspan=1 rowspan=1 > FINGERPRINT, EMR 63325-019, 2012-001435-31 </td><td colspan=1 rowspan=1 >  </td><td colspan=1 rowspan=1 >  </td><td colspan=1 rowspan=1 > Withdrawn </td><td colspan=1 rowspan=1 > Non-small Cell Lung Cancer (NSCLC) Stage III </td><td colspan=1 rowspan=1 > Other: Biological: MUC1 peptide specific immunotherapy, Drug: Cyclophosphamide (CPA) </td><td colspan=1 rowspan=1 > Phase 1 </td><td colspan=1 rowspan=1 > 0 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <td colspan=1 rowspan=2 > NCT00960115 Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy </td><td colspan=1 rowspan=1 > EMR063325-009 </td><td colspan=1 rowspan=1 > December 2008 </td><td colspan=1 rowspan=1 > May 2014 </td><td colspan=1 rowspan=1 > Completed </td><td colspan=1 rowspan=1 > Non-small Cell Lung Cancer </td><td colspan=1 rowspan=1 > Biological: cyclophosphamide + EMD531444 + BSC, Biological: Saline + Placebo + BSC </td><td colspan=1 rowspan=1 > Phase 1, Phase 2 </td><td colspan=1 rowspan=1 > 205 </td><td colspan=1 rowspan=1 > Merck KGaA, Merck Serono Co., Ltd., Japan </td></tr>
<tr> <td colspan=9 rowspan=1 > Results: The analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients with Stage III unresectable, locally advanced NSCLC who had received concurrent or sequential chemoradiotherapy (CRT), with a minimum of two cycles of platinum-based chemotherapy and radiation dose â‰¥50 Gy shows following results: Of the patients included in the Phase II part of the study, the majority had received concurrent CRT. </td></tr>
<tr> <td colspan=1 rowspan=2 > EudraCT: 2011-004822-85 A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer </td><td colspan=1 rowspan=1 > ABCSG-34 / EMR 63325-603 </td><td colspan=1 rowspan=1 > Jan 2012 </td><td colspan=1 rowspan=1 > May 2014 </td><td colspan=1 rowspan=1 > Active, not recruiting </td><td colspan=1 rowspan=1 > Breast Cancer </td><td colspan=1 rowspan=1 > L-BLP25 (Stimuvax), Cyclophosphamide (CPA), LETROZOLE, EPIRUBICIN, DOCETAXEL </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 400 </td><td colspan=1 rowspan=1 > ABCSG (Austrian Breast & Colorectal Cancer Study Group) </td></tr>
<tr> <td colspan=9 rowspan=1 > Results: 8 May 2012 Enrollment expected to be completed in May 2014 First results available end of 2014 26 Sept 2014 Enrollment of 400 patients completed </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01507103 Tecemotide (L-BLP25) in Rectal Cancer </td><td colspan=1 rowspan=1 > SPRINT, EMR063325-013, 2011-000847-25 </td><td colspan=1 rowspan=1 > February 2012 </td><td colspan=1 rowspan=1 > June 2014 </td><td colspan=1 rowspan=1 > Active, not recruiting </td><td colspan=1 rowspan=1 > Rectal Cancer </td><td colspan=1 rowspan=1 > Cyclophosphamide (CPA), Tecemotide (L-BLP25) </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 124 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <td class="highlighted"  colspan=1 rowspan=1 > NCT00828009 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery </td><td colspan=1 rowspan=1 > CDR0000632611, E6508 </td><td colspan=1 rowspan=1 > December 2010 </td><td colspan=1 rowspan=1 > January 2016 </td><td colspan=1 rowspan=1 > Recruiting </td><td colspan=1 rowspan=1 > Lung Cancer </td><td class="highlighted"  colspan=1 rowspan=1 > Biological: bevacizumab, Biological: emepepimut-S, Drug: carboplatin, Drug: cyclophosphamide, Drug: paclitaxel, Radiation: radiation therapy </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 55 </td><td colspan=1 rowspan=1 > Eastern Cooperative Oncology Group, National Cancer Institute (NCI) </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01462513 L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases </td><td colspan=1 rowspan=1 > LICC01 </td><td colspan=1 rowspan=1 > August 2011 </td><td colspan=1 rowspan=1 > September 2016 </td><td colspan=1 rowspan=1 > Recruiting </td><td colspan=1 rowspan=1 > Colon Carcinoma, Rectum Carcinoma </td><td colspan=1 rowspan=1 > Biological: L-BLP25, Biological: Placebo </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 159 </td><td colspan=1 rowspan=1 > Johannes Gutenberg University Mainz, Dr. Carl Schimanski </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01496131 Tecemotide (L-BLP25) in Prostate Cancer </td><td colspan=1 rowspan=1 > EMR 63325-015, BB-IND 7787 </td><td colspan=1 rowspan=1 > October 2011 </td><td colspan=1 rowspan=1 > August 2017 </td><td colspan=1 rowspan=1 > Recruiting </td><td colspan=1 rowspan=1 > Prostate Cancer </td><td colspan=1 rowspan=1 > Radiation: Radiation therapy, Drug: Goserelin, Drug: Cyclophosphamide, Drug: Tecemotide (L-BLP25) </td><td colspan=1 rowspan=1 > Phase 2 </td><td colspan=1 rowspan=1 > 48 </td><td colspan=1 rowspan=1 > EMD Serono, National Cancer Institute (NCI) </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT02049151 Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer </td><td colspan=1 rowspan=1 > START2, EMR 63325-021, 2013-003760-30 </td><td colspan=1 rowspan=1 > March 2014 </td><td colspan=1 rowspan=1 > July 2018 </td><td colspan=1 rowspan=1 > Recruiting </td><td colspan=1 rowspan=1 > Carcinoma, Non-Small-Cell Lung </td><td colspan=1 rowspan=1 > Drug: Tecemotide, Drug: Placebo, Drug: Cyclophosphamide (CPA), Drug: Saline (sodium chloride) </td><td colspan=1 rowspan=1 > Phase 3 </td><td colspan=1 rowspan=1 > 1002 </td><td colspan=1 rowspan=1 > EMD Serono </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01423760 Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials </td><td colspan=1 rowspan=1 > EMR 63325-011 </td><td colspan=1 rowspan=1 > January 2012 </td><td colspan=1 rowspan=1 > December 2019 </td><td colspan=1 rowspan=1 > Enrolling by invitation </td><td colspan=1 rowspan=1 > Non-Small Cell Lung Cancer, Multiple Myeloma </td><td colspan=1 rowspan=1 > Biological: Tecemotide, Other: No intervention </td><td colspan=1 rowspan=1 >  </td><td colspan=1 rowspan=1 > 262 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <td colspan=1 rowspan=1 > NCT01015443 Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population </td><td colspan=1 rowspan=1 > INSPIRE, EMR63325-012 </td><td colspan=1 rowspan=1 > December 2009 </td><td colspan=1 rowspan=1 > May 2020 </td><td colspan=1 rowspan=1 > Recruiting </td><td colspan=1 rowspan=1 > Non-Small Cell Lung Cancer </td><td colspan=1 rowspan=1 > Biological: Tecemotide (L-BLP25), Biological: Placebo </td><td colspan=1 rowspan=1 > Phase 3 </td><td colspan=1 rowspan=1 > 500 </td><td colspan=1 rowspan=1 > Merck KGaA </td></tr>
<tr> <th colspan=10 rowspan=1 > Note: Merck KGaA and Oncothyreon are not reporting in their annual reports on colorectal cancer trials and prostate cancer trials </th></tr>
</table> <br> <h3>Sentence(s)</h3>1. Tecemotide emepepimut-S known as BLP25 is a BLP25 liposome cancer vaccine. <br> <br><br><b>Categories:</b><br><b>Numerical:</b> Uses math skills for writing the sentence. Uses math operations (addition, subtraction, average, etc.), counting numbers, frequency of items, etc.<br> <b>Commonsense:</b> Uses commonsene knowledge about situations humans encounter in everyday life â€“ physical objects, word meanings, social or physical domains, peoples' intentions, etc.<br> <b>Temporal:</b> When concepts related to time and temporal aspects are required for writing the sentence. Duration, ordering, typical time of events, time differences between events.<br> <b>Table:</b> Writing the sentence requires knowledge from the table except: the highlighted cells, row and column headers, table titles, section titles, section texts.<br> <b>Out of Table:</b> Writing the sentence requires external knowledge that is not present in the table nor common sense. Knowledge about some specific domain comes under this category. </body></html>
